Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $23788.0.

  • Cumberland Pharmaceuticals' Capital Expenditures rose 5467.85% to $23788.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100187.0, marking a year-over-year decrease of 1122.19%. This contributed to the annual value of $66461.0 for FY2024, which is 7637.09% down from last year.
  • Cumberland Pharmaceuticals' Capital Expenditures amounted to $23788.0 in Q3 2025, which was up 5467.85% from $26486.0 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Capital Expenditures registered a high of $137255.0 during Q2 2022, and its lowest value of -$153528.0 during Q4 2022.
  • Its 5-year average for Capital Expenditures is $34279.6, with a median of $26986.0 in 2022.
  • Examining YoY changes over the last 5 years, Cumberland Pharmaceuticals' Capital Expenditures showed a top increase of 81060.17% in 2022 and a maximum decrease of 179700.45% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Capital Expenditures (Quarter) stood at $9047.0 in 2021, then crashed by 1797.0% to -$153528.0 in 2022, then skyrocketed by 131.7% to $48673.0 in 2023, then plummeted by 95.31% to $2283.0 in 2024, then surged by 941.96% to $23788.0 in 2025.
  • Its Capital Expenditures stands at $23788.0 for Q3 2025, versus $26486.0 for Q2 2025 and $47630.0 for Q1 2025.